Capricor seeks FDA approval of deramiocel for Duchenne based on encouraging data
The cell therapy biotech Capricor recently released new data from their Duchenne Muscular Dystrophy (DMD) trial work. The data have generated excitement in the patient advocacy community. The stock has skyrocketed. How exciting are these new data? CEO Linda Marbán is quite upbeat and I think it’s justified. The firm is now seeking FDA approval […]
Capricor seeks FDA approval of deramiocel for Duchenne based on encouraging data Read More »